Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394910 · ClinicalTrials.gov registry record · NA
Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT04394910 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 103 participants.
The verdict
NCT04394910, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
Infants diagnosed with intrauterine growth restriction are at increased risk for brain injury in the neonatal period, and eventually increased risk for adverse long-term neurodevelopmental outcomes. This kind of growth restriction is often caused by long-term placental insufficiency leading to chronic lack of oxygen in the brain during development. Pomegranate juice is one of the highest polyphenol-containing dietary supplements commercially available. Previous studies have shown that pomegranate-derived polyphenols are potent neuroprotective antioxidants with no proven side effects. The investigators hypothesize that maternal dietary supplementation with pomegranate juice during the last trimester of pregnancy will reduce the effects of exogenous stimuli contributing to placental insufficiency, and will enhance brain growth and development in the IUGR population.
Interventions
- DIETARY_SUPPLEMENT Pomegranate Juice
- DIETARY_SUPPLEMENT Placebo Juice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-01-16 |
| Est. Completion | 2022-02-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04394910
The ClinicalTrials.gov registry entry for NCT04394910 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pomegranate Juice is the first listed.
NCT04394910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04394910 about?
NCT04394910 is a clinical study titled "Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)". Infants diagnosed with intrauterine growth restriction are at increased risk for brain injury in the neonatal period, and eventually increased risk for adverse long-term neurodevelopmental outcomes. This kind of growth restriction is often caused by long-term placental insufficiency leading to chron...
What is the current status of trial NCT04394910?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2016-01-16. Estimated completion is 2022-02-26.
What interventions are being tested in trial NCT04394910?
The interventions under investigation include: Pomegranate Juice (DIETARY_SUPPLEMENT), Placebo Juice (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04394910?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.